Abstract
No public abstract is available from the verified source records.
Caitlin Costello, Brea Lipe, Andrew J Cowan, Jens Hillengass, P Leif Bergsagel, Xavier Leleu, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Yifah Yaron, Patrick P Ng, Banmeet Anand, Razia Akhtar, Al-Ola Abdallah
Abstract
Authors
No local reference links have been materialized yet.
Diagnosis and management of multiple myeloma: a review
10.1001/jama.2022.0003 · 2022
Multiple myeloma
10.1038/s41572-024-00529-7 · 2024
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
10.1016/s1470-2045(20)30756-7 · 2021
Updates on therapeutic strategies in the treatment of relapsed/refractory multiple myeloma
10.3390/cancers16172931 · 2024
Relapsed/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse
10.3390/curroncol30020179 · 2023
BCMA-targeted immunotherapy for multiple myeloma
10.1186/s13045-020-00962-7 · 2020
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
10.1038/s41408-024-01081-z · 2024
HPN217-3001: a phase 1/2 open-label, multicenter, dose escalation and dose expansion study of the safety, tolerability, and pharmacokinetics of HPN217, a BCMA-targeting T-cell engager, in patients with relapsed/refractory multiple myeloma
10.1182/blood-2020-136012 · 2020
Fc-engineering for modulated effector functions-improving antibodies for cancer treatment
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.3390/antib9040064 · 2020
Preclinical and nonclinical characterization of HPN217: a tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma
2018
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019
International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders
10.1016/s1470-2045(19)30309-2 · 2019
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
10.1200/jco.2015.61.2267 · 2015
Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety
10.3390/cancers15061819 · 2023
Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review
10.3390/jcm12175539 · 2023
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023
Linvoseltamab for treatment of relapsed/refractory multiple myeloma
10.1200/jco.24.01008 · 2024
HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors
10.1158/1535-7163.mct-23-0524 · 2024
Teclistamab: mechanism of action, clinical, and translational science
10.1111/cts.13717 · 2024
Racial disparities in multiple myeloma
2025
No additional external references are available.